Harrow (HROW) Total Non-Current Liabilities (2014 - 2024)
Harrow (HROW) posted Total Non-Current Liabilities of $291.2 million for Q3 2024, up 18.5% on a QoQ basis from $245.7 million in Q2 2024, and up 40.04% year-over-year from $208.0 million in Q4 2023.
Analysis
Harrow (HROW) Total Non-Current Liabilities (2014 - 2024) Analysis & Trends
Harrow has reported Total Non-Current Liabilities for 10 years, with the latest figure at $291.2 million in Q3 2024.
- On a quarterly basis, Total Non-Current Liabilities rose 40.04% year-over-year to $291.2 million in Q3 2024; TTM through Sep 2024 was $291.2 million, a 40.04% increase from a year earlier, with the FY2023 full-year figure at $239.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $291.2 million for Q3 2024 at Harrow, up from $245.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $291.2 million in Q3 2024, with the low at $27.6 million in Q1 2021.
- Average Total Non-Current Liabilities over 4 years is $147.1 million, with a median of $196.7 million recorded in 2023.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities retreated 11.21% in 2021, then jumped 40.04% in 2024.
- Over 4 years, Total Non-Current Liabilities stood at $29.8 million in 2020, then slipped by 7.59% to $27.6 million in 2021, then surged by 766.65% to $239.0 million in 2023, then gained by 21.82% to $291.2 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $291.2 million (Q3 2024), $245.7 million (Q2 2024), and $232.6 million (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 291.21 Mn |
| Jun 30, 2024 | 245.74 Mn |
| Mar 31, 2024 | 232.62 Mn |
| Dec 31, 2023 | 239.04 Mn |
| Sep 30, 2023 | 207.95 Mn |
| Jun 30, 2023 | 199.66 Mn |
| Mar 31, 2023 | 193.70 Mn |
| Mar 31, 2021 | 27.58 Mn |
| Dec 31, 2020 | 29.85 Mn |
| Sep 30, 2020 | 33.74 Mn |
| Jun 30, 2020 | 33.26 Mn |
| Mar 31, 2020 | 31.07 Mn |
| Dec 31, 2019 | 30.87 Mn |
| Sep 30, 2019 | 30.17 Mn |
| Jun 30, 2019 | 29.36 Mn |
| Mar 31, 2019 | 28.68 Mn |
| Dec 31, 2018 | 23.90 Mn |
| Sep 30, 2018 | 23.04 Mn |
| Jun 30, 2018 | 21.80 Mn |
| Mar 31, 2018 | 20.32 Mn |